Longevity pharmacology comes of age

Magalhães, João Pedro de

doi:10.1016/j.drudis.2021.02.015

Cited by 26 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2016 ), pointing instead to the importance in aging of in vivo accumulation of hyper-secretory senescent cells where neither a role of replicative senescence or telomere shortening is clearly implicated ( Campisi 2013 ). Continuing advances in the genetics of lifespan and discovery of longevity pathways and drugs ( de Magalhaes 2021 ) have not been matched by advances in understanding the causes and mechanisms of aging. Really, during the last two decades, biogerontology’s conceptual world view has taken a beating.…”

Section: An Emerging Paradigmatic Crisis In the Aging Fieldmentioning

confidence: 99%

“…Thus, the hallmarks of aging provides an account that is both intelligible and attractive to the anti-aging industry, including investors, which has grown substantially in recent years ( de Magalhães et al . 2017 ; de Magalhaes 2021 ). The list of hallmarks also provides a useful checklist for researchers studying specific diseases of aging, trying to understand their etiologies, and has generated further hallmarks lists, e.g.…”

Section: Arrival Of the Hallmarks Of Agingmentioning

confidence: 99%

See 1 more Smart Citation

The hoverfly and the wasp: A critique of the hallmarks of aging as a paradigm

Gems

Magalhães

2021

Ageing Research Reviews

Self Cite

View full text Add to dashboard Cite

With the goal of representing common denominators of aging in different organisms López-Otín et al. in 2013 described nine hallmarks of aging. Since then, this representation has become a major reference point for the biogerontology field. The template for the hallmarks of aging account originated from landmark papers by Hanahan and Weinberg (2000 , 2011 ) defining first six and later ten hallmarks of cancer. Here we assess the strengths and weaknesses of the hallmarks of aging account. As a checklist of diverse major foci of current aging research, it has provided a useful shared overview for biogerontology during a time of transition in the field. It also seems useful in applied biogerontology, to identify interventions (e.g. drugs) that impact multiple symptomatic features of aging. However, while the hallmarks of cancer provide a paradigmatic account of the causes of cancer with profound explanatory power, the hallmarks of aging do not. A worry is that as a non-paradigm the hallmarks of aging have obscured the urgent need to define a genuine paradigm, one that can provide a useful basis for understanding the mechanistic causes of the diverse aging pathologies. We argue that biogerontology must look and move beyond the hallmarks to understand the process of aging. In its normal state, then, a scientific community is an immensely efficient instrument for solving the problems or puzzles that its paradigms define. ( Kuhn 1962 ) p. 166.

show abstract

Section: An Emerging Paradigmatic Crisis In the Aging Fieldmentioning

confidence: 99%

Section: Arrival Of the Hallmarks Of Agingmentioning

confidence: 99%

The hoverfly and the wasp: A critique of the hallmarks of aging as a paradigm

Gems

Magalhães

2021

Ageing Research Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…As such, early identification and interventions for aging and age-related diseases are the basis for "healthy aging" in the general population. Aging research has achieved great success in elucidating the genetic pathways that underlie aging phenotypes, and the number of candidate anti-aging drugs discovered in model organisms has substantially grown [4]. However, no anti-aging drugs have currently been approved, largely because of a lack of reliable drug targets and effective methods for evaluating anti-aging efficacy.…”

Section: Introductionmentioning

confidence: 99%

Small-molecule fluorescence-based probes for aging diagnosis

Shi

Liu

Wang

et al. 2022

Acta Materia Medica

View full text Add to dashboard Cite

Aging is a time-dependent decline in physiological function that affects most organisms and is the major risk factor for many non-communicable diseases. The early diagnosis of aging is critical for the treatment of aging and aging-related diseases. In recent years, extensive efforts have attempted to accurately diagnose aging. To date, multiple types of fluorescent probes for various age-related biomarkers have been developed, with the aims of achieving rapid, precise diagnosis of the aging process and evaluating the efficacy of anti-aging drugs. This review summarizes recent research progress in small-molecule fluorescence-based probes for aging diagnosis, and further discusses the challenges and opportunities in this field.

show abstract

“…Among potential measures, pharmacological prevention of age-related disease development and progression is promising, as several drugs have been shown to slow down aging and extend lifespan in model organisms and/or to have beneficial effects in cell and animal models of age-related diseases. Several signaling pathways and molecular components have been identified as being targeted by those drugs that Biomolecules 2022, 12, 921 2 of 20 hence show promise for further development as treatments for age-related diseases and eventually as anti-aging drugs [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Monoterpenes as Sirtuin-1 Activators: Therapeutic Potential in Aging and Related Diseases

Sousa

Mendes

2022

Biomolecules

View full text Add to dashboard Cite

Sirtuin 1 (SIRT) is a class III, NAD+-dependent histone deacetylase that also modulates the activity of numerous non-histone proteins through deacylation. SIRT1 plays critical roles in regulating and integrating cellular energy metabolism, response to stress, and circadian rhythm by modulating epigenetic and transcriptional regulation, mitochondrial homeostasis, proteostasis, telomere maintenance, inflammation, and the response to hypoxia. SIRT1 expression and activity decrease with aging, and enhancing its activity extends life span in various organisms, including mammals, and improves many age-related diseases, including cancer, metabolic, cardiovascular, neurodegenerative, respiratory, musculoskeletal, and renal diseases, but the opposite, that is, aggravation of various diseases, such as some cancers and neurodegenerative diseases, has also been reported. Accordingly, many natural and synthetic SIRT1 activators and inhibitors have been developed. Known SIRT1 activators of natural origin are mainly polyphenols. Nonetheless, various classes of non-polyphenolic monoterpenoids have been identified as inducers of SIRT1 expression and/or activity. This narrative review discusses current information on the evidence that supports the role of those compounds as SIRT1 activators and their potential both as tools for research and as pharmaceuticals for therapeutic application in age-related diseases.

show abstract

Longevity pharmacology comes of age

Cited by 26 publications

References 13 publications

The hoverfly and the wasp: A critique of the hallmarks of aging as a paradigm

The hoverfly and the wasp: A critique of the hallmarks of aging as a paradigm

Small-molecule fluorescence-based probes for aging diagnosis

Monoterpenes as Sirtuin-1 Activators: Therapeutic Potential in Aging and Related Diseases

Contact Info

Product

Resources

About